Khushali Jhaveri, , shared a post on X:
“Bispecifics in the frontline?
In EPCORE NHL-5, Epcoritamab + pola-R-CHP in 1L DLBCL:
ORR 100%, CRR 97%
81% MRD– by C3D1 (ctDNA!)
Durable, deep responses. No ICANS. All CRS low grade.
Also: matched analysis of epco-R-miniCHOP vs R-miniCHOP shows 64% decreased risk of progression and 80% decreased risk of death.
CR rate: 92.8% vs 67.1%.
Small N, but a strong signal.”
Raul Cordoba, Chair of Community Stakeholder Committee at European Hematology Association (EHA), shared this post, adding:
“Impressive results!! We will need to wait for further follow-up to see the DoR. Great job!”
More posts featuring Khushali Jhaveri.